



(51) International Patent Classification:

A61K 45/06 (2006.01) A61K 31/225 (2006.01)
A61K 31/155 (2006.01) A61P 3/00 (2006.01)

(21) International Application Number:

PCT/EP2015/057615

(22) International Filing Date:

8 April 2015 (08.04.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PA 2014 70185 8 April 2014 (08.04.2014) DK
PA 2014 70187 8 April 2014 (08.04.2014) DK
PA 2014 70190 8 April 2014 (08.04.2014) DK

(71) Applicant: **NEUROVIVE PHARMACEUTICAL AB**
[SE/SE]; Medicon Village, Scheelevägen 2, S-223 81
Lund (SE).(72) Inventors: **ELMÉR, Eskil**; Mercuriusgatan 20, S-224 57
Lund (SE). **HANSSON, Magnus Joakim**; Artillerigatan
52, S-261 33 Landskrona (SE). **EHINGER, Karl Henrik
Johannes**; Södra Vägen 19, S-223 58 Lund (SE). **PIEL,
Sarah**; Laboratoriegatan 3, S-223 51 Lund (SE). **MOSS,
Steven**; 30 The Rookery, Balsham CB21 4EU (GB).(74) Agent: **CHAS. HUDE A/S**; H.C. Andersens Boulevard 33,
1780 København V (DK).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: SUCCINATE PRODRUGS FOR USE IN THE TREATMENT OF LACTIC ACIDOSIS OR DRUG-INDUCED SIDE-EFFECTS DUE TO COMPLEX I-RELATED IMPAIRMENT OF MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION

Figure 5



(57) Abstract: The present invention relates to a succinate prodrug for use in the treatment or prevention of lactic acidosis.